BioNTech aims to have multiple commercialised cancer drugs by 2030 as it shifts focus away from Covid-19 vaccines, CEO Ugur Sahin said at the J.P. Morgan Healthcare Conference in San Francisco.
“Our ambition is to build a fully integrated multiproduct oncology company, and 2026 is just the beginning of our road map,” Sahin said.
The Germany-headquartered company, which co-developed the first mRNA Covid-19 vaccine with Pfizer, has seen demand for Covid products fall and its share price remain far below the August 2021 peak. BioNTech says it will continue to make adaptive Covid-19 vaccines as needed but is prioritising oncology to drive future revenue.
BioNTech currently runs more than 25 Phase II and III oncology programmes and 10 novel-combination trials. Its cancer pipeline spans next-generation immunomodulators, antibody drug conjugates (ADCs) and mRNA cancer immunotherapies.
The company highlighted several lead candidates. Pumitamig, a PD-L1/VEGF bispecific antibody, is positioned as a potential next-generation immune-oncology standard; Bristol Myers Squibb in June 2025 agreed a deal worth up to $11 billion to co-develop the drug. Gotistobart, an anti-CTLA-4 therapy for lung cancer, has shown success in a Phase III trial. Some ADCs are being developed for pan-tumour use, while individualised mRNA vaccines are in trials for pancreatic, bladder and colorectal cancers. BioNTech strengthened its mRNA capabilities with the $1.25 billion acquisition of CureVac in June 2025.
Analysts at Citi welcomed the late-stage data flow and called BioNTech a differentiated play among traditional vaccine companies as it transforms into a commercial oncology firm.
Pumitamig is among five late-stage readouts expected in 2026 as the company enters a data-heavy period. “We are entering a phase of sustained clinical data output from 2026 to 2029, and we will provide regular updates on execution and progress. This pipeline supports multiple approval opportunities, and we are building launch readiness now, developing indication-specific expertise and advancing market access capabilities in the tumour types where we anticipate first launches,” Sahin said.
BioNTech expects to be a diversified multiproduct technology company by 2030.
In November the company raised its 2025 revenue guidance and ended the year with more than $17 billion in cash, cash equivalents and securities. CFO Ramón Zapata-Gomez said BioNTech will prioritise investing in its internal pipeline while remaining open to acquisitions and collaborations.
Leave a Reply